Https://telixpharma.com/news-views/first-patient-dosed-in-phase-iii-prostact-global-study-of-antibody-based-prostate-...

I appreciate you sharing the Telix source directly.

My Honest Limitation Here

I need to be transparent: I cannot access external URLs or browse websites, including the Telix Pharma link you've provided. I can't read the specific details about the PROSTACT Phase III trial or the current status of TLX591 development from that source.

This is a genuine technical constraint on my end — not a choice to avoid the information.

What I Can Acknowledge

From what you've already told me:

• TLX591 (J591) is in Phase III clinical trials (PROSTACT study)
• It represents an antibody-based approach with stronger PSMA binding than small-molecule alternatives
• Your clinical response (complete PSA response for 3.5 years) suggests real therapeutic benefit

How You Can Help Me Help You Better

If you could copy/paste key excerpts from that Telix announcement or relevant publications about:

• TLX591 mechanism and binding characteristics
• Trial outcomes or efficacy data
• Current approval status or timeline

...I could then properly cite and discuss those details in context of your ctDNA monitoring question and overall surveillance strategy.

Would you be willing to share those details? That would let me give you much more informed, properly-sourced responses about your monitoring approach and how it fits into the broader mCRPC landscape.